Related references
Note: Only part of the references are listed.Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000-2006
Benjamin Young et al.
CLINICAL INFECTIOUS DISEASES (2011)
Surface Localization of Glucosylceramide during Cryptococcus neoformans Infection Allows Targeting as a Potential Antifungal
Ryan Rhome et al.
PLOS ONE (2011)
Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity
Suzanne M. Noble et al.
NATURE GENETICS (2010)
Candida albicans sphingolipid C9-methyltransferase is involved in hyphal elongation
Takahiro Oura et al.
MICROBIOLOGY-SGM (2010)
Lipid Signaling in Pathogenic Fungi
Ryan Rhome et al.
ANNUAL REVIEW OF MICROBIOLOGY (2009)
Disruption of the sphingolipid Δ8-desaturase gene causes a delay in morphological changes in Candida albicans
Takahiro Oura et al.
MICROBIOLOGY-SGM (2008)
Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection
Marcio L. Rodrigues et al.
CLINICAL AND VACCINE IMMUNOLOGY (2007)
Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans
Philipp C. Rittershaus et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Recently discovered functions of glucosylceramides in plants and fungi
D Warnecke et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2003)
Characterization of glucosylceramides in Pseudallescheria boydii and their involvement in fungal differentiation
MR Pinto et al.
GLYCOBIOLOGY (2002)
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C-neoformans
C Luberto et al.
GENES & DEVELOPMENT (2001)
Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth
ML Rodrigues et al.
INFECTION AND IMMUNITY (2000)
Share Paper
